Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group
机构：[1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing.[2]Department of Hematology and Institute of Hematology, Stem Cell Transplantation and Celluar Therapy Division, Clinic Trial Center, West China Hospital, Sichuan University, Chengdu.四川大学华西医院[3]Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, P.R. China.[4]Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China. Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou.[5]Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou.河南省肿瘤医院[6]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China[7]State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing.
This study aimed to demonstrate the clinical outcomes of granulocyte colony-stimulating factor (G-CSF)/antithymocyte globulin (ATG), posttransplantation cyclophosphamide (PTCy) and PTCy combined with lowdose ATG (PTCy with ATGlow)-based haploidentical transplantation protocols in patients with haematologic malignancies. The comparisons were conducted via propensity score matching (PSM) analysis to balance the basic characteristics among different groups and were based on the transplantation data reported to the Chinese Bone Marrow Transplantation Registry Group (CBMTRG) from January 2020 to December 2022. For each patient in the PTCy or PTCy with ATGlow group, patients (at a 1:2 ratio) from the GCSF/ ATG group were selected. In total, the PTCy group (n=122) was matched with G-CSF/ATG Group 1 (n=230), and the PTCy+ATGlow group (n=123) was matched with G-CSF/ATG Group 2 (n=226). Compared with those in the PTCy group, the incidences of 28-day neutrophil engraftment (P=0.005), 100- day platelet engraftment (P=0.002), median time to neutrophil engraftment (P.
基金：
This work was supported by National Key Research and
Development Program of China (No. 2022YFA1103300), Major Program of
the National Natural Science Foundation of China (No. 82293630), Key
Program of the National Natural Science Foundation of China (No. 81930004),
the National Natural Science Foundation of China (No. 82100227), Peking
University Medicine Fund for world's leading discipline or discipline cluster
development (No.71003Y3035), Peking University People’s Hospital
Research and Development Funds (RS2023-02), and Clinical Medicine Plus
X - Young Scholars Project of Peking University, the Fundamental Research
Funds for the Central Universities (PKU2024LCXQ001).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|1 区医学
小类|2 区血液学
第一作者：
第一作者机构：[1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing.
共同第一作者：
通讯作者：
通讯机构：[1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing.[6]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China[7]State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing.
推荐引用方式(GB/T 7714)：
Xu Zheng-Li,Ji Jie,Wang San-Bin,et al.Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group[J].Haematologica.2024,doi:10.3324/haematol.2024.286040.
APA：
Xu Zheng-Li,Ji Jie,Wang San-Bin,Li Nai-Nong,Zhou Jian...&Huang Xiao-Jun.(2024).Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group.Haematologica,,
MLA：
Xu Zheng-Li,et al."Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group".Haematologica .(2024)
医学